<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954756</url>
  </required_header>
  <id_info>
    <org_study_id>APD-L0315</org_study_id>
    <nct_id>NCT03954756</nct_id>
  </id_info>
  <brief_title>Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer</brief_title>
  <official_title>Phase II Clinical Study of the Combination of Apatinib and PD1 in Treating Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With
      PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus
      Providing More Options for Patients With Advanced Gastric Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight
      patients) iv every 2 weeks. The efficacy and safety will be observed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>up to 2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 2 year</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, and partial response (CR
+ PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>up to 2 year</time_frame>
    <description>The time from the start of randomization to the first tumor recurrence/metastasis or the death of the subject for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>apatinib and PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib and PD1</intervention_name>
    <description>Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal
PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.</description>
    <arm_group_label>apatinib and PD-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients join the study voluntarily, sign a consent form, have good compliance, and
             comply with follow-up.

          2. To be confirmed to meet the clinical diagnosis standard, histologically or
             cytologically confirmed advanced Gastric Cancer.

          3. Failure of the second-line standard treatment regimen (disease progression), &gt;14 days
             from the last chemotherapy, chemotherapy regimen including fluorouracil (5-FU /
             capecitabine / teggio), oxaliplatin and irinotecan; Acceptable or not received
             bevacizumab/cetuximab/regofenib treatment.

          4. Aged 18-70 years old, both genders.

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.

          6. Life expectancy of at least 3 months.

          7. Patients must have at least 1 lesion that is measurable using RECIST v1.1 criteria.If
             the lesion receiving local therapy (radiotherapy, radiofrequency, interventional
             therapy, etc.) is the only lesion, definite imaging progress is required.

          8. the main organ functions of the patient shall meet the following standards within 7
             days before treatment：Blood routine examination standard (without blood transfusion
             within 7 days before enrollment）Hemoglobin ≥ 70 g/L; Absolute neutrophil count (ANC)
             ≥1.5×109/L; Platelet count ≥ PLT）≥80×109/L；Biochemical examination shall meet the
             following standards:serum total bilirubin (TBIL)≤1.5 times the upper limit of normal
             (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×upper
             limit of normal(ULN)；Serum creatinine (Cr)≤1.5ULN or creatinine removal rate
             (CCr)≥60ml/min；

          9. Women of childbearing age should agree to use contraceptives (such as intrauterine
             devices, contraceptives or condoms) during the study period and within 6 months after
             the end of the study; the serum or urine pregnancy test is negative within 7 days
             prior to study enrollment and must be Non-lactating patients; males should agree to
             patients who must use contraception during the study period and within 6 months after
             the end of the study period。

        Exclusion Criteria:

          1. Hypertension and unable to be controlled within normal level following treatment of
             anti-hypertension agents(within 3 months): systolic blood pressure &gt; 140 mmHg,
             diastolic blood pressure &gt; 90 mmHg；

          2. Diabetes blood sugar control is poor；

          3. Acute phase of cerebral infarction, or recovery period &lt;2 months；

          4. Has a variety of factors that affect the absorption of oral drugs (such as inability
             to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction);

          5. Patients with a risk of gastrointestinal bleeding may not be enrolled, including the
             following: (1) active digestive ulcer lesions and fecal occult blood (++); (2) nausea
             and hematemesis within 2 months Medical history. Simple fecal occult blood (+) is not
             an exclusion criterion；

          6. Coagulation abnormalities （INR&gt;1.5×ULN，APTT&gt;1.5×ULN）,with bleeding tendency;

          7. Urine protein ≥ ++ or confirmed 24 hour urine protein quantitation &gt; 1.0 g；

          8. Pregnant or lactating women;

          9. Within 2 weeks after treatment with cytotoxic drugs and radiotherapy;Has taken two or
             more oral targeted drugs；

         10. Except for other malignant tumors, basal cell carcinoma of the skin and cervical
             cancer in situ in the past 5 years；

         11. The investigator believes that there are any conditions that may damage the subject or
             result in the subject being unable to meet or perform the research request；

         12. Patients with severe liver and kidney dysfunction (grade 4) should be excluded;

         13. Those who are allergic to any component of apafitini mesylate should be excluded;

         14. Mental disorders history, or psychotropic drug abuse history；

         15. Previous use of regorafenib is not an exclusion criterion；

         16. According to the investigator's judgment, there are people with concomitant diseases
             that seriously endanger the safety of the patient or affect the patient's completion
             of the study;

         17. Surgery was performed within 4 weeks prior to the start of treatment, or patients with
             major trauma or fractures. Or there is an unhealed wound before treatment;

         18. Patients with severe heart disease, such as grade III or above (NYHA standard)
             congestive heart failure, or grade III or above (CCS standard) angina, or a history of
             myocardial infarction within 6 months prior to treatment, or an arrhythmia requiring
             medication;

         19. The patient has brain metastasis, meningeal metastasis;

         20. Active HBV infection and rejection of formal antiviral therapy;

         21. Active tuberculosis;

         22. Participants who have participated in any drug or medical device clinical trial within
             1 month prior to the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning Li</last_name>
    <phone>13526501903</phone>
    <email>lining97@126.com</email>
  </overall_contact>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

